(Q34734311)

4 August 2017

0 references

1 reference

title

Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis (English)

1 reference

4 August 2017

0 references

1 reference

1 reference

1 reference

1 reference

4

L Leibovici

1 reference

4 August 2017

L H Katz

1

1 reference

4 August 2017

A Fraser

series ordinal

2

1 reference

4 August 2017

A Gafter-Gvili

series ordinal

3

1 reference

4 August 2017

R Tur-Kaspa

series ordinal

5

1 reference

4 August 2017

publication date

1 February 2008

1 reference

Journal of Viral Hepatitis

4 August 2017

published in

1 reference

4 August 2017

volume

15

1 reference

4 August 2017

issue

2

1 reference

4 August 2017

page(s)

89-102

1 reference

Fulminant hepatic failure in leukaemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Reactivation of chronic hepatitis B virus infection by cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Fulminant hepatitis due to reactivation of chronic hepatitis B virus infection after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Effect of immunosuppressive and antiviral agents on hepatitis B virus replicationin vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies. Survey in Japan, 1987-1991.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Prevalence of hepatitis B virus marker positivity and evolution of hepatitis B virus profile, during chemotherapy, in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Results on preemptive or prophylactic treatment of lamivudine in HBsAg (+) renal allograft recipients: comparison with salvage treatment after hepatic dysfunction with HBV recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Hepatitis B virus DNA contains a glucocorticoid-responsive element

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Lamivudine for the treatment of hepatitis B virus reactivation following chemotherapy for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Effect of Am-80, a synthetic derivative of retinoid, on experimental arthritis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Prophylactic lamivudine prevents hepatitis B reactivation in chemotherapy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Effectiveness of prophylactic Anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Reactivation of hepatitis B virus infection with cytotoxic therapy in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Catastrophic heparin-induced thrombocytopenia/thrombosis syndrome related to the use of a Port-A-Cath in a breast cancer patient receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Lamivudine facilitates optimal chemotherapy in hepatitis B virus-infected children with hematological malignancies: a preliminary report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00902.X

10.1111/J.1365-2893.2007.00902.X

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference